Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. (Q43073125)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 May 2010

Language	Label	Description	Also known as
English	Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.	scientific article published on 5 May 2010

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

zoledronic acid

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Gunter von Minckwitz

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

H Eidtmann

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

R de Boer

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

N Bundred

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

A Llombart-Cussac

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

N Davidson

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

P Neven

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

J Miller

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

N Schenk

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

R Coleman

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

5 May 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2188-2194

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20444845%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Practical guidance for the management of aromatase inhibitor-associated bone loss

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

The safety of zoledronic acid

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Femoral neck bone loss predicts fracture risk independent of baseline BMD.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

A pooled analysis of bone marrow micrometastasis in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

New research findings on zoledronic acid: survival, pain, and anti-tumour effects

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ217

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43073125&oldid=1966943602"